Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Amylyx Pharmaceuticals (AMLX) FCF Margin (2021 - 2024)

Amylyx Pharmaceuticals (AMLX) has 4 years of FCF Margin data on record, last reported at 219.72% in Q4 2024.

  • For Q4 2024, FCF Margin rose 20755.0% year-over-year to 219.72%; the TTM value through Sep 2025 reached 575.17%, up 62332.0%, while the annual FY2024 figure was 192.0%, 19480.0% down from the prior year.
  • FCF Margin reached 219.72% in Q4 2024 per AMLX's latest filing, up from 9988.22% in the prior quarter.
  • Across five years, FCF Margin topped out at 219.72% in Q4 2024 and bottomed at 9988.22% in Q3 2024.
  • Average FCF Margin over 4 years is 2894.71%, with a median of 6.29% recorded in 2023.
  • Peak YoY movement for FCF Margin: skyrocketed 795306bps in 2023, then crashed -998205bps in 2024.
  • A 4-year view of FCF Margin shows it stood at 7374.74% in 2021, then skyrocketed by 97bps to 229.92% in 2022, then skyrocketed by 105bps to 12.17% in 2023, then soared by 1706bps to 219.72% in 2024.
  • Per Business Quant database, its latest 3 readings for FCF Margin were 219.72% in Q4 2024, 9988.22% in Q3 2024, and 6517.01% in Q2 2024.